Quest Diagnostics
DGX
$247.08
+3.86%
Quest Diagnostics Inc. is the largest independent clinical laboratory in the United States, operating a national network of roughly 2,400 patient service centers and generating over 97% of its revenue from clinical testing, anatomic pathology, esoteric testing, and substance abuse testing, supplemented by a smaller diagnostic solutions segment focused on clinical trials and risk-assessment services. As a scaled, capital-intensive diagnostics platform with approximately 57,000 employees, Quest occupies a defensive, volume-driven position in the healthcare sector, competing primarily with Labcorp and hospital-based labs on cost, breadth of test menu, and physician relationships. The current investor narrative centers on the company's accelerating organic growth — Q1 2026 revenue rose 9.2% year over year to $2.895 billion, the strongest quarterly growth in recent memory — alongside steady margin discipline and a rising dividend, which has drawn income-oriented and value-focused institutional interest. Debate among investors hinges on whether this growth is durable (driven by utilization recovery, esoteric test mix, and share gains) or whether it reflects a temporary boost that will normalize, especially given the stock's strong year-to-date run and the mixed analyst stance reflected in recent ratings actions.…
DGX
Quest Diagnostics
$247.08
Investment Opinion: Should I buy DGX Today?
Based on the synthesis of fundamental, valuation, and analyst data, the recommendation is Hold. The core thesis is that Quest Diagnostics is a fairly valued, defensive compounder with accelerating revenue growth but limited near-term upside, as the analyst consensus target of $246.73 implies only 5.0% upside from the current price of $235.02. The consensus recommendation is Buy with a mean of 2.12, but the modest upside suggests much of the good news is priced in.
Supporting evidence includes: 1) Revenue growth of 9.2% YoY in Q1 2026, the strongest in recent memory, driven by utilization recovery and esoteric testing; 2) Operating margin expansion to 13.8% from 13.0%, with net margin at 8.70%; 3) Strong free cash flow of $1.326 billion TTM, comfortably covering the 1.83% dividend yield with a 35.6% payout ratio; 4) Valuation at 19.56x trailing PE and 11.74x EV/EBITDA, which is fair relative to peers and the stock's own history. The PEG ratio of 1.43 suggests reasonable pricing relative to growth.
Key risks that could invalidate the thesis include: 1) Reimbursement pressure or competitive share loss that slows revenue growth below 5%; 2) Multiple compression if the PE reverts toward the low end of its historical range (15x); 3) Balance sheet constraints with debt-to-equity near 1.0 and a tight current ratio of 1.044. The rating would upgrade to Buy if the stock pulls back to the $210-$220 range (implying a PE near 15x) or if revenue growth accelerates above 10% for multiple quarters. It would downgrade to Sell if revenue growth decelerates below 5% or if operating margins contract. Overall, the stock appears fairly valued, trading in the middle-to-upper portion of its historical PE band, with limited margin of safety at current levels.
Sign up to view all
DGX 12-Month Price Forecast
Quest Diagnostics presents a balanced risk/reward profile. The company has demonstrated accelerating revenue growth and stable margins, but the stock has already rallied 35% YTD and trades at a fair valuation with minimal analyst upside. The low beta and dividend yield appeal to income-oriented investors, but the lack of a clear catalyst for multiple expansion limits upside. We would upgrade to bullish if revenue growth sustains above 8% for multiple quarters or if the stock pulls back to the $210-$220 range, improving the risk/reward. We would downgrade to bearish if revenue growth falls below 5% or if operating margins contract, signaling that the recent acceleration was temporary.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Quest Diagnostics's 12-month outlook, with a consensus price target around $246.73 and implied upside of -0.1% versus the current price.
Average Target
$246.73
0 analysts
Implied Upside
-0.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$204 - $265
Analyst target range
Coverage of Quest Diagnostics is solid, with 15 analysts contributing to the consensus, and the distribution leans constructive: the consensus recommendation is "buy" with a recommendation mean of 2.12 (where lower is more bullish), and the average target price of $246.73 implies roughly 5.0% upside from the current price of $235.02. The consensus EPS estimate of $14.82 (range $14.61–$15.08) and revenue estimate of $11.56 billion (range $11.43–$11.71 billion) suggest analysts expect continued but moderate growth. Sentiment is therefore mildly bullish but not euphoric, with the modest implied upside reflecting that much of the good news — the strong Q1 print and the stock's 35% YTD run — already appears priced in.
The target range spans $204 (low) to $265 (high), a spread of about 30% that signals meaningful disagreement about the company's trajectory. The high target of $265 implies roughly 12.8% upside and likely assumes sustained revenue acceleration, margin expansion, and possibly multiple re-rating toward the upper end of the historical PE band, while the low target of $204 implies about 13.2% downside and prices in margin compression, reimbursement pressure, or a normalization of the recent growth surge. Recent institutional ratings show a predominantly neutral-to-constructive posture — Baird, UBS, and Truist have maintained Neutral/Hold ratings through 2026, while Barclays (Overweight), Mizuho (Outperform), and Jefferies (Buy) remain more positive — indicating that while the sell-side sees value, conviction is not uniform, and the stock's low beta and defensive characteristics make it a holding for balanced portfolios rather than a high-conviction momentum call.
Drowning in data?
Find the real signal!
Bulls vs Bears: DGX Investment Factors
The bull case rests on accelerating revenue growth (9.2% YoY in Q1 2026), stable margins, strong free cash flow, and a reasonable valuation with a low-beta defensive profile. The bear case highlights that the stock has already run 35% YTD, analyst upside is minimal at 5%, the PE gap implies flat earnings growth, and the balance sheet is not fortress-like. Currently, the bull evidence is stronger because the fundamental acceleration is tangible and the valuation is not stretched, but the most important tension is whether the recent growth surge is durable or temporary. If growth normalizes to low single digits, the stock could face multiple compression; if it sustains above 7%, the shares could re-rate toward the high end of the historical PE band.
Bullish
- Revenue growth accelerating to 9.2%: Q1 2026 revenue of $2.895 billion grew 9.2% year over year, up from 5.9% in Q1 2025 and roughly 7.0% in Q4 2025. This acceleration suggests the company is gaining share and benefiting from utilization recovery and esoteric test mix, transforming it from a low-growth defensive name into a modest compounder.
- Margin expansion and stable profitability: Q1 2026 operating margin improved to 13.8% from 13.0% a year earlier, while net margin rose to 8.70% from 8.30%. Gross margin held steady at 32.5%, demonstrating cost discipline and volume leverage despite reimbursement pressure.
- Strong free cash flow and dividend coverage: Trailing twelve-month free cash flow is $1.326 billion, comfortably covering the $88 million quarterly dividend with a payout ratio of 35.6%. The dividend yield of 1.83% and consistent cash generation support shareholder returns and provide flexibility for acquisitions.
- Undemanding valuation with room to re-rate: The stock trades at a trailing PE of 19.56x and forward PE of 19.49x, near the middle of its historical 15x-22x range, with a PEG of 1.43 and EV/EBITDA of 11.74x. This moderate valuation leaves room for multiple expansion if growth proves durable.
Bearish
- Minimal analyst upside already priced in: The consensus average target price of $246.73 implies only 5.0% upside from the current price of $235.02, and the stock is trading at 84% of its 52-week range. Much of the good news from the strong Q1 print and 35% YTD run appears already reflected in the price.
- Narrow PE gap signals flat earnings growth: The trailing PE of 19.56x and forward PE of 19.49x are nearly identical, implying the market expects essentially no earnings growth over the next year. Consensus EPS of $14.82 is only marginally above the current run-rate, suggesting limited near-term earnings momentum.
- Balance sheet lacks flexibility: Debt-to-equity stands at 0.965 and the current ratio is a tight 1.044, with cash of only $393 million. The cash flow-to-debt ratio of 0.04 in the latest quarter indicates reliance on internal cash generation, leaving little room for unexpected shocks or large strategic investments.
- Reimbursement and competitive pressures: As a clinical lab, Quest faces persistent reimbursement pressure from payors and competition from Labcorp and hospital-based labs. Any acceleration in pricing declines or share loss could quickly erode the mid-single-digit growth that supports the current valuation.
DGX Technical Analysis
Quest Diagnostics is in a sustained uptrend, with the shares up 28.1% over the past year and 35.2% year to date, decisively outperforming the S&P 500's 16.2% and 12.1% gains over the same periods. At a current price of $235.02, the stock sits at roughly 84% of its 52-week range (52-week low of $171.18, high of $247.19), positioning it in the upper quartile of its annual band — a sign of persistent momentum but also of limited near-term headroom before it tests the highs. The relative strength readings reinforce this leadership, with 1-year relative strength of +11.9% and 3-month relative strength of +12.7% versus the market, indicating the stock has been a consistent source of alpha rather than a laggard bouncing off lows.
Short-term momentum, however, has cooled noticeably: the stock is down 1.16% over the past month while the S&P 500 fell 1.06%, producing a slightly negative relative strength of -0.10% and suggesting the recent consolidation is broadly market-driven rather than company-specific weakness. This 1-month softness contrasts with the still-robust 3-month gain of 15.7% and 6-month gain of 17.7%, a divergence that points to a healthy pause or digestion phase within a larger uptrend rather than a trend reversal, particularly since the pullback has been shallow (maximum drawdown of just -11.94%). The stock's low beta of 0.549 implies it should continue to move less than the broader market in either direction, which helps explain the muted magnitude of the recent decline and supports the case for treating this as a temporary pullback.
Key technical levels are well defined: support rests near the 52-week low of $171.18, with intermediate support likely around the $225–$230 area where the stock consolidated in late August, while resistance sits at the 52-week high of $247.19. A breakout above $247 would signal renewed institutional accumulation and likely open the door to new all-time highs, whereas a breakdown below $225 would suggest the momentum trade is unwinding and could expose the stock to a deeper mean-reversion toward the $200 region. With a beta of 0.549 — roughly 45% less volatile than the market — position sizing can be more aggressive than for a high-beta name, but the low beta also means the stock may lag in sharp risk-on rallies, making it better suited to defensive or income-oriented portfolios than to momentum-chasing strategies.
Beta
0.55
0.55x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$171-$249
Price range past year
Annual Return
+36.8%
Cumulative gain past year
| Period | DGX Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | -2.4% |
| 3m | +24.9% | +2.2% |
| 6m | +27.3% | +14.8% |
| 1y | +36.8% | +14.6% |
| ytd | +42.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DGX Fundamental Analysis
Quest's revenue trajectory is clearly re-accelerating: Q1 2026 revenue of $2.895 billion grew 9.2% year over year, a marked acceleration from the 5.9% growth in Q1 2025 ($2.652 billion) and the roughly 7.0% growth in Q4 2025 ($2.806 billion). The sequential progression from $2.652 billion (Q1 2025) to $2.761 billion (Q2 2025) to $2.816 billion (Q3 2025) to $2.806 billion (Q4 2025) to $2.895 billion (Q1 2026) shows a steady upward march, with the diagnostic information services segment contributing $2.832 billion, or 97.8% of the quarter's revenue. This consistent mid-to-high single-digit growth, unusual for a mature lab company, implies the investment case has shifted from a low-growth defensive story to a modest compounder, likely supported by utilization recovery, esoteric testing mix, and share gains against hospital labs.
Profitability remains solid and stable, with Q1 2026 net income of $252 million on a 8.70% net margin, up from $220 million and an 8.30% net margin in Q1 2025, while gross margin held at 32.5% (gross profit of $942 million) versus 32.5% a year earlier. Operating income of $399 million produced a 13.8% operating margin, an improvement from 13.0% in the prior-year quarter, and EBITDA of $434 million equates to a 15.0% EBITDA margin — though this was depressed by a $37 million D&A figure that appears understated relative to the $140–$147 million quarterly run rate seen in other periods. The company's trailing net margin of 8.99% and operating margin of 14.53% are consistent with the low-double-digit operating margins typical of large-scale clinical labs, where reimbursement pressure is offset by volume leverage and cost controls.
Balance sheet and cash flow metrics are adequate but not fortress-like: debt-to-equity stands at 0.965, the current ratio is a tight 1.044, and ROE is 13.8% with ROA of 6.4%. Free cash flow on a trailing-twelve-month basis is $1.326 billion, comfortably covering the $88 million in quarterly dividends (a payout ratio of 35.6% and a dividend yield of 1.83%), and Q1 2026 operating cash flow of $278 million less $114 million of capex produced $164 million of free cash flow. The company's cash position of $393 million against meaningful debt and a cash flow-to-debt ratio of just 0.04 in the latest quarter highlights that Quest relies on consistent internal cash generation rather than balance-sheet liquidity to fund operations, acquisitions ($38 million in Q1 2026), and shareholder returns — a manageable but not overly flexible financial profile.
Quarterly Revenue
$2.9B
2026-03
Revenue YoY Growth
+9.2%
YoY Comparison
Gross Margin
32.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DGX Overvalued?
Because Quest is solidly profitable — Q1 2026 net income of $252 million and trailing EPS positive — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 19.56x and a forward PE of 19.49x, an unusually narrow gap that implies the market expects essentially flat earnings growth over the next year, consistent with the analyst consensus EPS estimate of $14.82 versus the current run-rate. The PEG ratio of 1.43 suggests the shares are reasonably priced relative to expected growth, while the price-to-sales ratio of 1.75x and EV/EBITDA of 11.74x frame the valuation as moderate for a healthcare services name.
Relative to the broader medical diagnostics and research sector, Quest's 19.6x trailing PE and 1.75x PS ratio sit at a modest discount to the premium multiples often commanded by high-growth diagnostics and life-science tools companies, though the comparison is imperfect given Quest's lower-growth, lab-services model. The EV/EBITDA of 11.74x is close to the mid-teens range typical of large-cap healthcare services peers, and the 2.69x price-to-book ratio is undemanding for a business with a 13.8% ROE. On balance, the valuation appears fair rather than stretched, with the discount to higher-multiple diagnostics peers justified by Quest's slower growth, capital intensity, and reimbursement exposure.
Historically, Quest's PE has ranged from roughly 15x to 22x over the past several years, and the current 19.6x sits in the middle-to-upper portion of that band — above the 17.9x seen in mid-2025 but below the 21.6x recorded in Q1 2026 and well below the 43.9x spike in Q4 2022 when earnings were depressed. The PS ratio of 1.75x is near the low end of its historical range (which has run from about 5.7x to 7.7x on the data provided, though those figures appear to reflect a different share-count basis), suggesting the market is not pricing in heroic expectations. Overall, the valuation implies the market is paying a fair price for steady mid-single-digit growth and reliable cash returns, leaving room for multiple expansion if the recent revenue acceleration proves durable.
PE
19.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Quest Diagnostics carries moderate financial and operational risks. The debt-to-equity ratio of 0.965 and current ratio of 1.044 indicate a leveraged balance sheet with limited short-term liquidity, while cash of $393 million is modest relative to debt. The cash flow-to-debt ratio of just 0.04 in the latest quarter highlights reliance on consistent internal cash generation to fund operations, acquisitions ($38 million in Q1 2026), and dividends. Additionally, revenue is highly concentrated in clinical testing, which accounts for 97.8% of sales, exposing the company to reimbursement pressure and volume fluctuations.
Market and competitive risks are significant. The stock trades at a trailing PE of 19.56x, near the upper-middle of its historical 15x-22x range, leaving room for multiple compression if growth slows. Competition from Labcorp and hospital-based labs could pressure pricing and market share. The low beta of 0.549 reduces market correlation but also means the stock may lag in strong risk-on rallies. Recent analyst actions show mixed sentiment, with Baird, UBS, and Truist maintaining Neutral/Hold ratings, while Barclays, Mizuho, and Jefferies are more positive, indicating a lack of uniform conviction.
In a worst-case scenario, a combination of reimbursement cuts, loss of a major contract, and a slowdown in utilization could cause revenue growth to decelerate to low single digits, leading to earnings misses and multiple compression. The 52-week low of $171.18 represents a 27.2% decline from the current price of $235.02, and the analyst low target of $204 implies 13.2% downside. A more severe scenario, such as a recession or competitive disruption, could push the stock toward the $170-$180 range, resulting in a loss of 23-28% from current levels. Investors should be prepared for potential drawdowns of this magnitude given the stock's recent strong run.
FAQ
The key risks include: 1) Reimbursement pressure — as a clinical lab, DGX is highly exposed to Medicare and commercial payor rate cuts, which could compress margins (gross margin is 32.5%); 2) Competitive threats — Labcorp and hospital-based labs compete on price and breadth, potentially eroding market share; 3) Balance sheet constraints — debt-to-equity of 0.965 and a current ratio of 1.044 limit financial flexibility, with cash of only $393 million; 4) Valuation risk — at 19.56x PE, the stock is not cheap, and any earnings miss could trigger multiple compression. Additionally, the low beta of 0.549 means it may underperform in strong bull markets, and the recent 35% YTD run increases the risk of profit-taking.
Our 12-month forecast for DGX includes three scenarios: Bull case (25% probability) targets $265-$280, assuming revenue growth above 8% and multiple expansion to 21-22x PE; Base case (55% probability) targets $240-$255, assuming 6-7% revenue growth and stable margins, aligning with the analyst average target of $246.73; Bear case (20% probability) targets $180-$204, assuming revenue growth decelerates to 3-4% and PE compresses to 15-16x. The base case is most likely, supported by the company's steady cash flows and defensive characteristics. The key assumption is that revenue growth remains in the mid-single-digit range, with no major reimbursement cuts or competitive disruptions.
DGX appears fairly valued. The trailing PE of 19.56x and forward PE of 19.49x are near the middle of its historical 15x-22x range, and the PEG ratio of 1.43 suggests reasonable pricing relative to expected growth. The EV/EBITDA of 11.74x is in line with large-cap healthcare services peers, and the price-to-sales of 1.75x is moderate. Compared to high-growth diagnostics companies, DGX trades at a discount, but that is justified by its slower growth and capital intensity. The market is pricing in steady mid-single-digit growth and reliable cash returns, not heroic expectations. If growth accelerates, the multiple could expand toward 22x, implying a price near $265; if growth slows, it could compress to 15x, implying a price near $180.
DGX is a reasonable buy for income-oriented, low-risk investors, but it is not a high-conviction growth play. The stock trades at $235.02, with a consensus target of $246.73 implying 5.0% upside, and offers a 1.83% dividend yield. The company has shown accelerating revenue growth (9.2% YoY in Q1 2026) and stable margins, but the valuation is fair at 19.56x trailing PE, and the balance sheet has moderate leverage (debt-to-equity 0.965). The biggest downside risk is a reversion to the 52-week low of $171.18, representing 27% downside, if growth stalls. For long-term investors seeking defensive exposure with income, DGX is a good buy on pullbacks; for those seeking high growth, it may be less appealing.
DGX is better suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company operates in a mature, defensive industry with steady cash flows, a 1.83% dividend yield, and low beta (0.549), making it ideal for income-oriented, risk-averse investors. Short-term trading is less attractive due to the stock's low volatility and the fact that it has already rallied 35% YTD, leaving limited near-term upside (analyst target implies 5% upside). The stock's earnings visibility is high, but growth is modest, so total returns will likely come from a combination of dividends and gradual earnings growth rather than rapid multiple expansion. Long-term holders can benefit from the defensive nature and potential for continued dividend increases.
